DMTK * Stock Overview
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
DermTech, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$55.65 |
52 Week High | US$55.65 |
52 Week Low | US$55.65 |
Beta | 2.69 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -96.59% |
Recent News & Updates
Recent updates
Shareholder Returns
DMTK * | MX Biotechs | MX Market | |
---|---|---|---|
7D | 0% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how DMTK * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how DMTK * performed against the MX Market.
Price Volatility
DMTK * volatility | |
---|---|
DMTK * Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: DMTK * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DMTK *'s volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 279 | Bret Christensen | www.dermtech.com |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions.
DermTech, Inc. Fundamentals Summary
DMTK * fundamental statistics | |
---|---|
Market cap | Mex$943.27m |
Earnings (TTM) | -Mex$2.18b |
Revenue (TTM) | Mex$255.05m |
3.7x
P/S Ratio-0.4x
P/E RatioIs DMTK * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DMTK * income statement (TTM) | |
---|---|
Revenue | US$14.02m |
Cost of Revenue | US$14.84m |
Gross Profit | -US$813.00k |
Other Expenses | US$118.82m |
Earnings | -US$119.63m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.55 |
Gross Margin | -5.80% |
Net Profit Margin | -853.02% |
Debt/Equity Ratio | 0% |
How did DMTK * perform over the long term?
See historical performance and comparison